Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week High – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high on Thursday . The company traded as high as $102.24 and last traded at $101.1490, with a volume of 69081 shares traded. The stock had previously closed at $98.07.

Analyst Ratings Changes

DNTH has been the topic of several recent research reports. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Trading Up 3.2%

The firm has a market cap of $5.53 billion, a PE ratio of -24.47 and a beta of 1.20. The firm has a 50 day moving average price of $87.16 and a 200-day moving average price of $71.17.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In related news, SVP Adam M. Veness sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares in the company, valued at $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.02% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. boosted its holdings in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares in the last quarter. First Horizon Corp purchased a new position in Dianthus Therapeutics in the first quarter valued at about $32,000. Virtus Investment Advisers LLC lifted its position in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock valued at $260,000 after acquiring an additional 416 shares during the period. Royal Bank of Canada boosted its stake in shares of Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.